Form 4 for CTSO Cytosorbents Corp
Accepted 2026-09-16 16:05:30 ET · period of report 2026-09-14 · accession 0001104659-26-108247 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-09-16 16:05 | 2026-09-14 | CTSO | Capponi Vincent | Pres, COO | P - Purchase | $6.05 | +2,073 | 40.4K | +5% | +$12.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-14 | P | A | 1,800 | $6.07 | 40,114 | D | — | — | (F1) This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. (F2) Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015; (F3) (continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and (F4) (continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person. (F5) Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026. |
| 2 | Common | Common Stock | 2026-09-14 | P | A | 273 | $5.90 | 40,387 | D | — | — | (F1) This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. (F2) Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015; (F3) (continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and (F4) (continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person. (F5) Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026. |